Please provide your email address to receive an email when new articles are posted on . Last week, the FDA announced accelerated approval of pralatrexate, the first drug approved for peripheral T-cell ...

Discover comprehensive details about Pralatrexate Solution, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced new data demonstrating the anticancer activity of its investigational drug, pralatrexate, in colon, ovarian, ...

The major degradation products of pralatrexate drug product formed under hydrolytic and light stress conditions were identified, synthesized, and characterized using advanced spectroscopic techniques ...

Review the side-effects of Pralatrexate Solution as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Researchers analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) -- which led to the FDA approval of pralatrexate in September 2009. Forty percent of study ...

December 12, 2008 (San Francisco, California) — The investigational agent pralatrexate (Allos Therapeutics, Inc) shows promise in relapsed and refractory peripheral T-cell lymphoma, according to data ...

Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma WESTMINSTER, Colo.--(BUSINESS WIRE)--Aug ...

Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Background: Pralatrexate, a ...

Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). Background: Pralatrexate (FOLOTYN) is a targeted ...

The major degradation products of pralatrexate drug product formed under hydrolytic and light stress conditions were identified, synthesized and characterized using advanced spectroscopic techniques ...

September 26, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval and orphan drug status for pralatrexate injection (Folotyn, Allos Therapeutics, Inc) as a single agent ...